Project Sierra
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Opportunity
A pharmaceutical company established in 2016, serves as a manufacturer, distributor, and MAH with 5 branded products, OTC offerings, generic dossiers, and ongoing CDMO contracts across 19 countries, certification for capsules, tablets, semi-solids, suppositories, and injectables (new line under investment), while providing CMO/CDMO, out-licensing, QA/QC, warehousing, and cosmetic manufacturing services, achieving $7.7M net revenue but -$5.4M EBITDA due to heavy capex in the new injectables facility, and actively seeking acquisition or strategic investment.
Company Profile
Established in 2016, this pharmaceutical company operates as a manufacturer, distributor, and Marketing Authorization Holder (MAH) with a portfolio of 5 branded products, OTC offerings, generic dossiers, and several ongoing CDMO contracts.
Capabilities
Certified for capsules, tablets, film-coated tablets, semisolids, and suppositories, with production spanning nine pharmaceutical areas. The company also manufactures cosmetics and maintains advanced laboratories, providing comprehensive services including CMO/CDMO, out-licensing, QA/QC, warehousing, and picking/packaging.
Financial Highlights
Net revenue of $7.7 million, with EBITDA of -$5.4 million driven by substantial investment in a new
injectables production line within the manufacturing plant, positioning the company for expanded capabilities in high-value sterile and injectable forms.
Investment Opportunity
The company is actively seeking acquisition or strategic investment, offering a modern platform with diversified revenue from own products, generics, and CDMO services, proven regulatory compliance, broad geographic distribution, and significant growth potential following major capex
in injectables to capture demand in expanding markets.